
ERRATA

The March 10, 2015, article by Den et al, entitled “Genomic Classifier Identifies Men With Adverse Pathology After Radical Prostatectomy Who Benefit From Adjuvant Radiation Therapy” (J Clin Oncol 33:944-951, 2015), contained errors. In Figures 2A, 2B, 4A, and 4B, data in the first and third rows of the “No. at risk” tables below the figure parts were inadvertently transposed.

In Figure 2A, in the first row of the table, the number of patients at risk in the “CAPRA-S < 3” group was given as 79 at 0 years after radiotherapy (RT), 35 at 5 years after RT, and 16 at 10 years after RT, whereas it should have been **10** at 0 years after RT, **6** at 5 years after RT, and **0** at 10 years after RT. In the third row of the table, the number of patients at risk in the “CAPRA-S > 5” group was given as 10 at 0 years after RT, 6 at 5 years after RT, and 0 at 10 years after RT, whereas it should have been **79** at 0 years after RT, **35** at 5 years after RT, and **16** at 10 years after RT.

In Figure 2B, in the first row of the table, the number of patients at risk in the “GC < 0.4” group was given as 34 at 0 years after RT, 14 at 5 years after RT, and 5 at 10 years after RT, whereas it should have been **77** at 0 years after RT, **44** at 5 years after RT, and **11** at 10 years after RT. In the third row of the table, the number of patients at risk in the “GC > 0.6” group was given as 77 at 0 years after RT, 44 at 5 years after RT, and 11

at 10 years after RT, whereas it should have been **34** at 0 years after RT, **14** at 5 years after RT, and **5** at 10 years after RT.

In Figure 4A, in the first row of the table, the number of patients at risk in the “RT PSA < 0.1” group was given as 15 at 0 years after RT, 7 at 5 years after RT, and 3 at 10 years after RT, whereas it should have been **12** at 0 years after RT, **7** at 5 years after RT, and **2** at 10 years after RT. In the third row of the table, the number of patients at risk in the “RT PSA > 0.5” group was given as 12 at 0 years after RT, 7 at 5 years after RT, and 2 at 10 years after RT, whereas it should have been **15** at 0 years after RT, **7** at 5 years after RT, and **3** at 10 years after RT.

In Figure 4B, in the first row of the table, the number of patients at risk in the “RT PSA < 0.1” group was given as 43 at 0 years after RT, 18 at 5 years after RT, and 6 at 10 years after RT, whereas it should have been **20** at 0 years after RT, **10** at 5 years after RT, and **4** at 10 years after RT. In the third row of the table, the number of patients at risk in the “RT PSA > 0.5” group was given as 20 at 0 years after RT, 10 at 5 years after RT, and 4 at 10 years after RT, whereas it should have been **43** at 0 years after RT, **18** at 5 years after RT, and **6** at 10 years after RT.

The online version has been corrected in departure from the print. *Journal of Clinical Oncology* apologizes for the error.

DOI: 10.1200/JCO.2015.61.9759; published April 20, 2015

The November 1, 2014, article by Guimbaud et al, entitled “Prospective, Randomized, Multicenter, Phase III Study of Fluorouracil, Leucovorin, and Irinotecan Versus Epirubicin, Cisplatin, and Capecitabine in Advanced Gastric Adenocarcinoma: A French intergroup (Fédération Francophone de Cancérologie Digestive, Fédération Nationale des Centres de Lutte Contre le Cancer, and Groupe Coopérateur Multidisciplinaire en Oncologie) Study” (J Clin Oncol 32:3520-3526, 2014), contained errors.

In the Treatment Administered section, under First-Line Chemotherapy, “The median number of cycles received was two (range, one to seven) in the ECX arm and three (range, one to 18) in the FOLFIRI arm” should read “The median number

of cycles received was **six (range, three to 21)** in the ECX arm and **12 (range, four to 72)** in the FOLFIRI arm.” Also in the Treatment Administered section, under Second-Line Chemotherapy, “The median number of cycles received was one (range, one to five) in the ECX arm and two (range, one to 11) in the FOLFIRI arm” should read “The median number of cycles received was **three (range, three to 15)** in the ECX arm and **eight (range, four to 44)** in the FOLFIRI arm.”

The online version has been corrected in departure from the print. The authors apologize for the mistakes.

DOI: 10.1200/JCO.2015.62.0682; published April 20, 2015